Germline P/LP variants in GATA2, ETV6 and RUNX1 predispose heterozygotes to increased risk for developing hematological malignancies, early malignancy (as a group), and increased all-cause mortality for RUNX1. This increased risk of malignancy and death adds support to the proposed addition of RUNX1 to the ACMG/AMP secondary findings list, as identification of these variants in patients would lead to increased surveillance and better clinical management. Here, RUNX1 is linked to hematologic disorder.